Integrative Management for Patients Dealing with Neuropathic Pain

Explore integrative management strategies for neuropathic pain to enhance your healing journey and overall well-being.

Abstract

This educational post examines the intricate challenges of managing severe, refractory neuropathic pain through a detailed case study of a 70-year-old female patient. Her symptoms originated from a complicated thoracentesis procedure that led to pneumothorax and chest tube placement, superimposed on a background of postherpetic neuralgia. From my perspective as a dual-licensed practitioner in chiropractic and advanced nursing with functional medicine training, I walk through our team’s clinical journey. We cover nuanced opioid management—including selection, rotation, titration, and Morphine Milligram Equivalent (MME) calculations—along with the essential role of adjuvant medications for neuropathic pain. I explain how to recognize and address opioid-induced hyperalgesia (OIH) and detail how we integrate functional medicine, chiropractic care, rehabilitation, and regenerative therapies such as ultrasound-guided Platelet-Rich Plasma (PRP) injections, all under coordinated medical oversight. This post highlights our clinic’s collaborative model, where chiropractic care complements conventional and functional approaches to deliver comprehensive, patient-centered relief for complex neuropathic and procedural pain. Our goal is to offer an evidence-based roadmap for clinicians managing acute-on-chronic and refractory neuropathic pain, including advanced options like methadone and intrathecal delivery systems.

Our Collaborative Practice: A Model of Integrative Care

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, we have built a multidisciplinary environment that delivers truly comprehensive care. I am Dr. Alex Jimenez, holding credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and board-certified Family Nurse Practitioner (FNP-BC), plus certifications in functional medicine (CFMP, IFMCP). This breadth of training lets me approach health and pain through structural, neurological, and systemic lenses.

Our practice operates under the medical direction of Dr. Maria Guadalupe Cardenas, MD, a board-certified Internist with over 40 years of experience (NPI #1164426749; Texas MD License #J2933). As Medical Director and Collaborative Physician, she provides critical oversight to ensure safety and efficacy across all treatment plans. This physician-led collaboration—pairing chiropractic expertise with internal medicine, functional medicine, and regenerative services—forms the foundation of modern integrative injury and pain care.

For patients with complex neuropathic pain, this model means we simultaneously address biomechanical and structural contributors through chiropractic care while managing physiological and pharmacological needs under direct medical supervision. The result is personalized, multimodal strategies that target root drivers of suffering rather than isolated symptoms. We now further enhance this synergy through regenerative interventions, such as PRP, to support tissue and nerve recovery.

A Deep Dive into a Complex Pain Case: Initial Presentation

I want to share a complex neuropathic pain case that tested our team and yielded valuable clinical insights. This case, based on a real patient (whom we will call DM), illustrates modern strategies for refractory nerve pain in the setting of procedural complications.

DM, a 70-year-old female, presented to the hospital with a pleural effusion requiring thoracentesis. The procedure was complicated by a large pneumothorax, leading to chest tube placement and admission to the medicine service for observation and further management. She also carried a history of shingles several months earlier and had been experiencing persistent thoracic neuropathic-type discomfort that she and her husband attributed to postherpetic neuralgia.

What began as a planned same-day procedure evolved into a prolonged hospital stay dominated by severe, poorly controlled pain. While some discomfort at the chest tube site was anticipated, her symptoms far exceeded expectations and localized along a thoracic dermatomal distribution.

Patient Background and Initial Examination

We performed a comprehensive history and physical examination to guide care.

• Social History: Married with no children. Former smoker, infrequent alcohol use, no illicit substance history.
• Family History: Both parents had passed away from chronic respiratory conditions.
• Home Medications: Omeprazole, ibuprofen, levothyroxine, citalopram, amitriptyline, potassium, progesterone, estradiol, and various vitamins/supplements.
• Review of Systems: Notable for approximately 20-pound weight loss, anorexia, fatigue, and constipation—symptoms likely exacerbated by uncontrolled pain and reduced oral intake.
• Physical Examination:
  • General: Thin, chronically ill-appearing but not in acute distress.
  • Cardiovascular: Regular rate and rhythm.
  • Pulmonary: Decreased breath sounds on the right; no increased work of breathing.
  • Musculoskeletal: Tenderness to palpation over the lower right chest and back in a clear T4–T8 dermatomal pattern. No visible rash or acute inflammation. Chest tube site clean, dry, and intact.
  • Extremities: Mild (1+) bilateral lower extremity edema.
• Laboratory Findings: Mostly unremarkable except for hypoalbuminemia, hypomagnesemia, and mild leukocytosis.

The Pain Management Consult and the Nature of the Pain

Our pain management team was consulted on hospital day eight. By then, DM had been hospitalized for over a week, primarily for pain control and resolution of the pneumothorax. The day prior, she had undergone Video-Assisted Thoracoscopic Surgery (VATS) with pleural exploration to address ongoing pleural space issues. Pain persisted and worsened after chest tube removal.

She described her pain as “chronic nerve pain, and now worse,” with her husband referencing postherpetic neuralgia. The pain localized precisely to the prior chest tube site and T4–T8 dermatomes, manifesting as “a thousand stinging electric shocks.” This classic neuropathic quality—combined with allodynia to light touch and deep palpation—pointed to nerve injury and central sensitization rather than purely nociceptive or inflammatory sources.

A Thorough Pain Assessment: The PQRSTU Algorithm

We used the PQRSTU framework for precise characterization:

• P (Precipitating, Palliating, Previous Treatment): Pain was continuous with no clear relieving or aggravating factors. Prior gabapentin for suspected postherpetic neuralgia had been discontinued due to lack of benefit and worsening lower extremity edema.
• Q (Quality): Severe, stinging, electric-shock sensations.
• R (Region, Radiation): Right-sided, strictly following the T4–T8 dermatomal pattern; tender to both light and deep palpation.
• S (Severity): Current 5/10; tolerable goal 3/10.
• T (Temporal Aspects): On Dilaudid PCA after the VATS procedure, provided short-lived relief before pain returned intensely within 30–45 minutes.
• U (Impact on You): Debilitating—preventing concentration, ambulation, eating, and any consideration of discharge.

Current Pain Management Regimen

Upon assuming care, her regimen included:

• Dilaudid (hydromorphone) PCA: 0.3 mg bolus every 15 minutes PRN (3.6 mg used in prior 24 hours).
• MS Contin (morphine sulfate extended-release): 15 mg every 12 hours (home dose).
• Acetaminophen PRN (unused).
• Oxycodone/acetaminophen 5/325 mg (two doses taken for breakthrough).
• Toradol (ketorolac) IV (one dose in 24 hours).
• Bowel regimen: Miralax and senna.
• Promethazine for nausea.

This regimen was clearly inadequate for the neuropathic component.

Strategizing Treatment: Targeting Neuropathic Pain

Neuropathic pain arises from nervous system dysfunction and responds poorly to opioids alone. We targeted it with mechanism-specific adjuvants.

• Central mechanisms (brain/spinal cord upregulation): Antiepileptics such as gabapentinoids stabilize hyperexcitable neurons. When poorly tolerated, alternatives like carbamazepine or oxcarbazepine may be considered.
• Peripheral mechanisms (nerve endings and dorsal root ganglia): SNRIs (e.g., duloxetine, venlafaxine) and TCAs (e.g., amitriptyline, nortriptyline) enhance descending inhibition. Topical agents (lidocaine patches, high-concentration capsaicin) provide localized relief.

Many patients require combination therapy addressing both central and peripheral drivers.

Our Initial Interventions

1. Started low-dose pregabalin (25 mg TID) to minimize edema risk seen previously with gabapentin; planned slow titration.
2. Scheduled acetaminophen 1000 mg every 8 hours for consistent central analgesia and synergy with other agents.
3. Continued home MS Contin 15 mg BID.
4. Added dexamethasone (alternating with promethazine) for anti-inflammatory and antiemetic effects.
5. Encouraged appropriate PCA use to quantify total opioid needs before transition.

Complications and Course Adjustments

Initial improvement occurred, but dizziness, intermittent confusion, and mild resting tremors developed—attributed to pregabalin. It was discontinued, and low-dose amitriptyline was initiated. Neurology consultation (unaware of our rationale) stopped the amitriptyline and restarted pregabalin. The PCA was discontinued per protocol and replaced with PRN IV hydromorphone, causing rapid pain escalation. Tremors and confusion recurred. Dronabinol (started for poor appetite) was identified as a contributor to hallucinations in this elderly patient and was stopped, resolving that issue.

A Critical Turning Point: Identifying the Drivers of Refractory Pain

After VATS stabilized the acute pleural space issues, pain continued to escalate despite adjustments. We recognized the dominant neuropathic character—intercostal neuralgia and central sensitization from procedural nerve irritation and possible postherpetic contributions. MRI and EMG (ordered by neurology) were negative for acute central pathology but showed mild peripheral polyneuropathy, not explaining the severe, localized thoracic symptoms.

Recognizing Opioid-Induced Hyperalgesia (OIH)

As pain worsened with rising opioid doses and she developed myoclonus and hallucinations, OIH became evident. This paradoxical state of heightened pain sensitivity arises from chronic opioid exposure.

Key physiological mechanisms:

• NMDA receptor activation leading to central sensitization.
• Spinal dynorphin upregulation enhances excitatory transmission.
• Brainstem descending facilitation instead of inhibition.
• Protein kinase C activation promotes allodynia and hyperalgesia.

Clinical red flags:

• Worsening/spreading pain despite dose increases.
• Myoclonus, twitching, restlessness.
• Allodynia (e.g., pain from a blood pressure cuff).
• Neurotoxicity progressing to delirium or hallucinations.

When OIH is suspected, we evaluate for neuroexcitatory metabolites (e.g., morphine-3-glucuronide), rotate opioids, and aggressively optimize non-opioid adjuvants.

Movement Medicine: Chiropractic Care- Video

Optimizing Opioids: The Art of Opioid Titration and Rotation

With uncontrolled pain and clear OIH, we shifted to structured opioid rotation and titration. Key principles include:

• Mu-receptor functional selectivity differences among opioids.
• Lipophilic agents (e.g., methadone) require slower titration (every 3–7 days) due to tissue accumulation; shorter-acting agents allow faster adjustments.

Titration Guidelines:

• Mild–moderate pain: Increase total daily dose 25–50%.
• Moderate–severe pain: Increase 50–100%.
• PRN dosing: Typically 10–15% of the total daily opioid requirement every 3–4 hours.

Calculating Morphine Milligram Equivalents (MMEs) — Essential for Safe Rotation:

• Oral morphine: 1 mg = 1 MME
• Oral hydrocodone: 1 mg = 1 MME
• Oral oxycodone: 1 mg = 1.5 MME
• IV hydromorphone: 1 mg = 20 MME
• Oral hydromorphone: 1 mg = 4 MME

When rotating, reduce the calculated MME by 25–50% to account for incomplete cross-tolerance.

Case Progression: Basal-Bolus Strategy and PCA Management

As oral intake declined, we initiated a morphine PCA after calculating 24-hour MME, converting to IV equivalent with safety reduction, and splitting into basal plus bolus. Pain remained 9/10 with breakthrough awakenings, prompting basal increase to 1 mg/hour (bolus 0.5 mg q15min). Due to an inadequate response and the patient’s report that hydromorphone was more effective, we rotated to a hydromorphone PCA (basal 0.2 mg/hour, bolus 0.3 mg q15min). Even at this level (MME ~486 mg/day), relief remained poor—highlighting that dose escalation alone was insufficient.

Advanced Strategies: Methadone and Intrathecal Pumps

With standard approaches failing, we advanced to specialized options after thorough goals-of-care discussions with the patient and family.

Methadone offers unique benefits for refractory neuropathic pain and OIH because one isomer acts as an NMDA receptor antagonist, directly countering central sensitization. It is inexpensive, highly lipophilic, and lacks neurotoxic metabolites, making it suitable in renal/hepatic impairment. Risks include very long half-life (slow titration every 4–7 days), QTc prolongation (baseline ECG required; avoid if QTc >450 ms), and need for strict adherence. We initiated methadone 5 mg every 8 hours and titrated cautiously to 10 mg every 8 hours.

Because the family preferred not to manage methadone at home, we consulted an anesthesiologist for an intrathecal pain pump. This delivers microdoses directly into the CSF (a typical conversion example: 10 mg IV morphine ≈ 0.1 mg intrathecal morphine), providing profound analgesia with dramatically reduced systemic exposure and side effects. It is ideal for intractable neuropathic pain, unacceptable systemic opioid effects, or when further dose escalation is limited.

Integrating Chiropractic Care and Regenerative PRP Therapy for Enhanced Outcomes

While advanced pharmacology stabilized the acute crisis, my role as a chiropractor proved essential for addressing the mechanical and peripheral contributors that perpetuate neuropathic pain. Protective muscle guarding, restricted thoracic mobility, and costovertebral joint dysfunction from pleural irritation and chest tube trauma can mechanically irritate intercostal nerves and sustain central sensitization.

• Neuro-mechanical assessment focused on rib mechanics, thoracic segmental mobility, and paraspinal/intercostal tone. Gentle, low-force mobilizations and adjustments restored biomechanical function, reduced afferent nociceptive bombardment to the spinal cord, and helped attenuate central wind-up.
• Soft-tissue and myofascial work targeted trigger points and fascial restrictions in the thoracic paraspinals and intercostals, decreasing referred pain and allodynia while improving local circulation and tissue extensibility.
• Breath mechanics and autonomic modulation training emphasized diaphragmatic breathing to reduce thoracic rigidity, lower sympathetic arousal, and enhance vagal tone—thereby decreasing pain perception and associated nausea.

These interventions were coordinated closely with Dr. Cardenas to ensure hemodynamic stability and respect procedural constraints during the inpatient phase.

To further target peripheral nerve and tissue healing, we incorporated ultrasound-guided Platelet-Rich Plasma (PRP) therapy as part of the regenerative component of care. PRP concentrates the patient’s own platelets and growth factors (PDGF, TGF-β, VEGF, etc.), which can modulate neuroinflammation, support axonal repair, and promote healing of irritated intercostal nerves and surrounding musculature/fascia. In this case, targeted perineural or paravertebral PRP applications at the affected T4–T8 levels complemented the pharmacological and chiropractic efforts by addressing local tissue drivers of ongoing neuropathic input. This multimodal layering—chiropractic restoration of mechanics + regenerative biological support + optimized pharmacotherapy—aims to reduce the overall pain burden, reduce long-term medication needs, and improve functional recovery.

A Journey to Improved Function and Quality of Life

DM remained hospitalized for 45 days. After careful goals-of-care discussions, she received a hydromorphone intrathecal pain pump (basal 0.25 mg/hour). This achieved tolerable pain levels. We successfully weaned the PCA and began tapering methadone.

With the acute phase stabilized, she transitioned to an outpatient integrative program that included ongoing chiropractic care for thoracic mobility and soft-tissue optimization plus a series of ultrasound-guided PRP treatments to support nerve and tissue recovery. She was discharged home, able to eat for pleasure, ambulate with assistance, and meaningfully engage with her husband. Nausea was well-controlled when it recurred. With continued coordinated care, her pain remained manageable, and she experienced meaningful restoration of function and quality of life. Her husband expressed deep appreciation for the time and comfort the team provided through this comprehensive, compassionate approach.

References

• Angst, M. S., & Clark, J. D. (2006). Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology, 104(3), 570–587.
• Bruera, E., & Sweeney, C. (2002). Methadone use in cancer patients with pain: A review. Journal of Palliative Medicine, 5(1), 127–138. (Adapted for neuropathic/OIH context)
• Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. British Journal of Anesthesia, 101(1), 62–70.
• Davis, M. P., & Inturrisi, C. E. (1999). Methadone pharmacokinetics and clinical applications. Supportive Care in Cancer, 7(6), 427–438.
• Deer, T. R., et al. (2017). The Polyanalgesic Consensus Conference (PACC): Recommendations for intrathecal drug delivery. Neuromodulation, 20(2), 155–176.
• Dowell, D., et al. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR, 71(3), 1–95.
• Finnerup, N. B., et al. (2015). Pharmacotherapy for neuropathic pain in adults: systematic review and meta-analysis. Lancet Neurology, 14(2), 162–173.
• Finnerup, N. B., et al. (2021). Neuropathic pain: pharmacological management update. Lancet Neurology, 20(10), 834–844.
• Mao, J. (2002). Mechanisms of central sensitization in chronic pain. Anesthesiology, 96(3), 583–587.
• Nielsen, S., et al. (2017). Opioid-induced hyperalgesia in humans: A review. Pain, 158(7), 1139–1154.
• Tang, Y., et al. (2021). Breathing interventions and autonomic modulation in pain. Pain Reports, 6(4), e967.
• Webster, L. R., & Choi, Y. (2015). Opioid rotation and incomplete cross-tolerance. Pain Medicine, 16(4), 764–771.

Additional clinical insights drawn from our integrative practice experience with multimodal neuropathic pain protocols, chiropractic biomechanics, and regenerative applications.

Clinical Observations and Practice Resources

• Dr. Alex Jimenez’s clinical insights: https://dralexjimenez.com/
• Professional profile: https://www.linkedin.com/in/dralexjimenez/

SEO Tags: Complex Neuropathic Pain Management, Postherpetic Neuralgia, Intercostal Neuralgia, Thoracic Radiculopathy, Opioid Rotation, Morphine Milligram Equivalents, Integrative Chiropractic Care, PRP Therapy, Regenerative Medicine for Nerve Pain, Functional Medicine, Pain Assessment PQRSTU, Adjuvant Analgesics, Multidisciplinary Care, Opioid-Induced Hyperalgesia OIH, Intrathecal Pain Pump, Methadone for Neuropathic Pain, Evidence-Based Multimodal Analgesia, Central Sensitization, El Paso TX Pain Clinic, Dr. Alex Jimenez, Dr. Maria Cardenas, Chiropractic for Neuropathic Pain, Ultrasound-Guided PRP Injections